諾和諾德裁員約9,000人 削全年經營溢利增長預測
丹麥藥廠諾和諾德(Novo Nordisk)宣布裁員約9,000人,約佔全球員工總數的11.5%,預計將產生80億丹麥克朗(約12.6億美元)的一次性成本。
生產減肥藥Wegovy的諾和諾德表示,今次裁員為為轉型計劃的一部分,旨在簡化組織架構,提高決策速度,並將資源重新分配到在糖尿病及肥胖症領域的增長機會。
公司表示,在一次性成本的影響下,預計全年經營溢利增長介乎4%至10%,低於此前預測的10%至16%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.